Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
14 nov. 2023 07h00 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
Pharma Two B Announces Publication of Positive Phase 3 Study Results of P2B001, an Investigational Treatment for Early Parkinson’s Disease, in Movement Disorders
09 nov. 2023 08h30 HE
|
PHARMA TWO B LTD
Demonstrated that P2B001 provides benefits comparable with commercially used doses of marketed pramipexole-ER (PramiER) while minimizing associated daytime sleep–related and dopaminergic side effects...
US Neurologists Emphasize Tremendous Unmet Treatment Need in Parkinson's Disease, According to Spherix Global Insights
07 nov. 2023 10h41 HE
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Parkinson's disease (PD) is the second-most prevalent neurodegenerative disorder following Alzheimer's disease, affecting an estimated one...
Groundbreaking study reveals link between air pollution and incidence of Parkinson’s disease
31 oct. 2023 18h07 HE
|
Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center
Phoenix, Oct. 31, 2023 (GLOBE NEWSWIRE) -- A new study led by researchers at Barrow Neurological Institute has found that people living in regions with median levels of air pollution have a 56...
Digital Brain Health Market Predicted to Reach US$ 382.9 billion by 2031, Growing at a 7.3% CAGR Says, Transparency Market Research
26 oct. 2023 04h33 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The digital brain health market was valued at US$ 184.7 billion in 2021. The market is...
Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
04 oct. 2023 07h00 HE
|
Gain Therapeutics, Inc.
BETHESDA, Md., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
12 sept. 2023 09h25 HE
|
Gain Therapeutics, Inc.
First drug candidate identified with Gain’s proprietary computational drug discovery platform SEE-Tx® to enter clinical development phase BETHESDA, Md., Sept. 12, 2023 (GLOBE...
Brain Implants Market to hit USD 10 billion by 2032, says Global Market Insights Inc.
10 sept. 2023 19h30 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Sept. 10, 2023 (GLOBE NEWSWIRE) -- Brain Implants Market size is expected to be worth USD 10 billion by 2032. The growing burden of neurological disorders along with the...
Pharma Two B to Present Additional Phase 3 Positive Results of P2B001, a once-daily, fixed-dose combination of low-dose pramipexole and low-dose rasagiline, at 2023 International Congress of Parkinson’s Disease and Movement Disorders®
28 août 2023 07h00 HE
|
PHARMA TWO B LTD
Sub-group analyses of patients with early Parkinson's disease (PD) at different age groups or baseline disease severities who were treated with P2B001 showed consistently greater symptomatic control...
Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease
22 août 2023 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the National Institute of Aging (NIA), has...